Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
May 23, 2024 07:10 ET
|
Tourmaline Bio, Inc.
Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June 9, 2024
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
May 23, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
May 23, 2024 07:00 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of...
Blue Mountain Appoints Chief Growth Officer to Spearhead Global Expansion and Strategic Partnerships in Life Sciences Sector
May 21, 2024 09:00 ET
|
Blue Mountain
Blue Mountain names Keith Pensabene as Chief Growth Officer, leading global growth and strategic partnerships in the life sciences sector.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
May 21, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women
May 21, 2024 08:00 ET
|
Amplexd Therapeutics Inc.
GAITHERSBURG, MD, May 21, 2024 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical stage patient-scientist-led biotech company specializing in accessible...
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
May 20, 2024 07:00 ET
|
Ocugen
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes
May 20, 2024 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2...
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
May 20, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women
May 19, 2024 20:00 ET
|
Amplexd Therapeutics Inc.
GAITHERSBURG, MD, May 20, 2024 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical stage patient-scientist-led biotech company specializing in accessible...